Upper Gastrointestinal Disorders - USMLE Step 2

SECTION 1

Historical Context & Motivation

Upper gastrointestinal (GI) disorders encompass a broad range of pathology affecting the esophagus, stomach, and duodenum, and they remain among the most common reasons for outpatient gastroenterology referrals and emergency department visits worldwide. Historically, the understanding of these conditions evolved from purely anatomical descriptions toward a sophisticated appreciation of mucosal defense mechanisms, acid secretion physiology, and the role of infectious agents. The pivotal discovery that Helicobacter pylori (H. pylori) causes peptic ulcer disease fundamentally transformed treatment paradigms, shifting the field from palliative acid suppression toward curative antimicrobial therapy. Today, clinicians must integrate knowledge of motility disorders, malignancy risk stratification, acid-related injury, and mucosal immunology to manage these patients effectively.

1823 • William Beaumont's Gastric Fistula Studies

Beaumont's experiments on Alexis St. Martin provided the first direct observations of gastric acid secretion and motility in a living human, laying the foundation for gastric physiology.

1910 • Schwarz's Dictum — 'No Acid, No Ulcer'

Karl Schwarz articulated the principle that peptic ulceration requires gastric acid, driving decades of research into antisecretory therapies including antacids, H₂-receptor antagonists, and proton pump inhibitors.

1982 • Discovery of Helicobacter pylori

Barry Marshall and Robin Warren identified the spiral bacterium in gastric biopsy specimens and demonstrated its causal role in chronic gastritis and peptic ulcer disease, earning the 2005 Nobel Prize in Physiology or Medicine.

1989 • Introduction of Proton Pump Inhibitors

Omeprazole became widely available, offering profound and sustained acid suppression that revolutionized management of GERD, Zollinger-Ellison syndrome, and erosive esophagitis.

2010s • Endoscopic Advances & Barrett's Surveillance

High-definition endoscopy, chromoendoscopy, and radiofrequency ablation refined the detection and treatment of Barrett's esophagus with dysplasia, reducing the need for esophagectomy in select patients.

Despite these advances, upper GI disorders continue to pose diagnostic and therapeutic challenges. The central clinical question remains: how does a clinician rapidly differentiate benign acid-related disease from potentially life-threatening conditions such as upper GI bleeding, perforation, or malignancy — and how should management be prioritized in both ambulatory and acute settings?

SECTION 2

Core Principles & Definitions

The pathophysiology of upper GI disorders can be understood through a framework balancing aggressive factors (acid, pepsin, bile, H. pylori, NSAIDs) against protective factors (mucus-bicarbonate barrier, mucosal blood flow, prostaglandins, epithelial restitution). When this balance is disrupted, a spectrum of disease emerges ranging from functional dyspepsia to frank ulceration and hemorrhage. A solid grasp of these foundational concepts enables the clinician to approach board-style vignettes and real patients with a structured differential diagnosis.

Gastroesophageal Reflux Disease (GERD)

Chronic retrograde flow of gastric contents into the esophagus causing heartburn, regurgitation, and potential mucosal injury. Pathogenesis involves transient lower esophageal sphincter relaxations, hiatal hernia, and impaired esophageal clearance.

Peptic Ulcer Disease (PUD)

Ulceration of the gastric or duodenal mucosa primarily caused by H. pylori infection or NSAID use. Complications include hemorrhage, perforation, and gastric outlet obstruction.

Upper GI Bleeding

Hemorrhage proximal to the ligament of Treitz, presenting as hematemesis, melena, or hematochezia in brisk bleeds. The Glasgow-Blatchford and Rockall scores guide risk stratification and need for intervention.

Barrett's Esophagus

Intestinal metaplasia of the distal esophageal squamous epithelium to specialized columnar epithelium, representing a premalignant condition with a 0.5% annual risk of progression to esophageal adenocarcinoma.

Gastric Malignancy

Includes adenocarcinoma (most common), lymphoma (MALToma), gastrointestinal stromal tumors (GIST), and carcinoid tumors. H. pylori is classified as a Group 1 carcinogen for gastric adenocarcinoma.

✦

KEY TAKEAWAY

Think of the gastric mucosa as a castle wall: the mucus-bicarbonate layer is the moat, prostaglandins are the sentries maintaining the fortifications, and mucosal blood flow is the supply chain that repairs damage. NSAIDs disable the sentries by inhibiting cyclooxygenase, while H. pylori tunnels beneath the moat itself. Understanding this balance between aggression and defense is the single most important principle for approaching upper GI pathology on boards and in clinical practice.

SECTION 3

Visual Explanation — Anatomy & Pathology Map

Anatomic map of the upper GI tract illustrating the typical locations of major disorders. Note that squamous cell carcinoma arises in the upper and middle esophagus, while adenocarcinoma develops at the gastroesophageal junction in the setting of Barrett's metaplasia. Duodenal ulcers on the anterior wall tend to perforate, whereas posterior wall ulcers erode into the gastroduodenal artery causing hemorrhage — a classic board association.

The diagram above illustrates a recurring theme in upper GI disorders: pathology is anatomically predictable. GERD occurs at the gastroesophageal junction where sphincter incompetence permits acid reflux. Duodenal ulcers are found in the duodenal bulb where acid load from gastric hypersecretion is highest, and they are strongly associated with H. pylori colonization of the gastric antrum, which disrupts somatostatin-mediated feedback inhibition of gastrin release. Gastric ulcers favor the lesser curvature and incisura angularis, regions where mucosal blood flow is relatively tenuous. Understanding these anatomic relationships enables rapid pattern recognition in clinical vignettes.

SECTION 4

Pathophysiology & Mechanisms

Acid Secretion Physiology

Gastric acid is produced by parietal cells in the gastric body and fundus via the H⁺/K⁺-ATPase (proton pump) on the apical membrane. Three major stimulatory pathways converge on the parietal cell: acetylcholine from vagal efferents acting on muscarinic M₃ receptors, histamine from enterochromaffin-like (ECL) cells acting on H₂ receptors, and gastrin from G cells acting on cholecystokinin B (CCK-B) receptors. Somatostatin, released from antral D cells, provides the principal inhibitory feedback. This physiology is directly relevant to pharmacologic management, as proton pump inhibitors (PPIs) irreversibly block the final common pathway of acid secretion.

PROTON PUMP REACTION

H⁺(intracellular) + K⁺(luminal) ⇌ H⁺(luminal) + K⁺(intracellular)

The H⁺/K⁺-ATPase exchanges intracellular H⁺ for luminal K⁺ against a concentration gradient of approximately 10⁶-fold. PPIs (e.g., omeprazole) form a covalent disulfide bond with cysteine residues on this pump, producing irreversible inhibition. Recovery requires synthesis of new pump molecules (half-life ≈ 18 hours).

H. pylori Pathogenesis

H. pylori colonizes the gastric antral mucosa by producing urease, which hydrolyzes urea to ammonia and CO₂, creating a locally alkaline microenvironment that protects the organism from gastric acid. Virulence factors including CagA (cytotoxin-associated gene A) and VacA (vacuolating cytotoxin) mediate mucosal injury by disrupting tight junctions, inducing inflammatory cytokines, and promoting apoptosis. In the antrum, H. pylori-driven inflammation suppresses D-cell somatostatin release, leading to unchecked gastrin secretion and acid hypersecretion — the principal mechanism underlying duodenal ulcer formation. In contrast, pangastritis reduces the parietal cell mass, producing a hypochlorhydric state that increases the risk of gastric ulcer, atrophic gastritis, intestinal metaplasia, and ultimately gastric adenocarcinoma via the Correa cascade.

GERD Pathophysiology

The pathogenesis of GERD is multifactorial: transient lower esophageal sphincter relaxations (TLESRs) account for the majority of reflux episodes. Contributing factors include a mechanically defective LES (resting pressure < 10 mmHg), hiatal hernia (which separates the LES from the crural diaphragm), impaired esophageal peristalsis, delayed gastric emptying, and obesity-related increases in intra-abdominal pressure. The esophageal squamous epithelium, lacking the protective mucus-bicarbonate barrier present in the stomach, is particularly vulnerable to acid-pepsin injury, which produces the characteristic inflammatory cascade of erosive esophagitis. Chronic reflux can lead to columnar metaplasia (Barrett's esophagus), which carries the risk of dysplasia and malignant transformation.

This flowchart contrasts the two dominant pathways of mucosal injury. H. pylori produces either antral-predominant disease (leading to duodenal ulcers via acid hypersecretion) or pangastritis (leading to gastric ulcers and the Correa cascade toward adenocarcinoma). NSAIDs impair mucosal defense by suppressing prostaglandin synthesis. Both pathways converge on the same complications: hemorrhage, perforation, obstruction, and malignancy.

SECTION 5

Detailed Classification & Diagnosis

Alarm Features (Red Flags) in Upper GI Disorders

⚠

ALARM FEATURES REQUIRING EGD

The mnemonic VBAD helps recall indications for urgent esophagogastroduodenoscopy: Vomiting (persistent), Bleeding (hematemesis or melena), Anemia (iron deficiency), Dysphagia/odynophagia. Additional red flags include unintentional weight loss (>5% in 6 months), palpable abdominal mass, lymphadenopathy, and new-onset dyspepsia in patients aged ≥ 55 years.

Peptic Ulcer Disease: Gastric vs. Duodenal

Feature	Gastric Ulcer	Duodenal Ulcer
Location	Lesser curvature, incisura angularis	Duodenal bulb (first portion)
Acid levels	Normal or low (mucosal defense impaired)	High (acid hypersecretion)
Pain pattern	Worsened by eating (30 min postprandial)	Improved by eating; worse 2–5 hrs after meals and at night
H. pylori association	~70%	~90–95%
Malignancy risk	Yes — biopsy edges to exclude adenocarcinoma	Extremely rare — biopsy not routinely required
Weight change	Weight loss (food aversion)	Weight gain (eating relieves pain)
Perforation anatomy	Free air; left subphrenic abscess	Anterior → perforation; Posterior → GDA hemorrhage

High-yield comparison of gastric versus duodenal ulcer features for USMLE Step 2

H. pylori Diagnostic Testing

Test	Invasive?	Use Case	Notes
Urea breath test	No	Test of cure (preferred); initial diagnosis	Hold PPIs ≥2 wk, antibiotics ≥4 wk before testing
Stool antigen	No	Test of cure (alternative); initial diagnosis	Same PPI and antibiotic washout required
Serology (IgG)	No	Screening in high-prevalence areas	Cannot confirm eradication (remains positive)
Rapid urease test (CLO)	Yes (EGD)	During endoscopy	Biopsy from antrum placed in urea-containing gel; color change = positive
Histology	Yes (EGD)	Gold standard; assesses inflammation, metaplasia	Silver stain (Warthin-Starry) or immunohistochemistry

H. pylori testing modalities

GERD Diagnosis & Staging

GERD is diagnosed clinically when typical symptoms (heartburn, regurgitation) respond to an empiric PPI trial. Esophagogastroduodenoscopy (EGD) is indicated when alarm features are present, when symptoms are refractory to 8 weeks of PPI therapy, or for Barrett's screening in high-risk patients (chronic GERD > 5 years, male sex, age > 50, obesity, Caucasian race, tobacco use, family history). 24-hour ambulatory pH monitoring remains the gold standard for quantifying acid exposure and is particularly useful when endoscopy is normal but symptoms persist, as it can distinguish true reflux from functional heartburn. The DeMeester score > 14.72 on pH testing is considered abnormal. High-resolution esophageal manometry is essential before anti-reflux surgery to exclude achalasia or severe hypomotility.

SECTION 6

Worked Clinical Vignette

Clinical Vignette: 55-Year-Old Male with Epigastric Pain and Melena

1
Step 1 — Identify the Presentation

A 55-year-old man with a history of chronic low back pain managed with daily ibuprofen (800 mg TID) presents with 3 days of worsening epigastric pain, two episodes of black tarry stools, and lightheadedness. Vital signs reveal HR 110 bpm, BP 95/60 mmHg, and orthostatic changes. CBC shows hemoglobin 8.2 g/dL (baseline 14 g/dL). The presentation of melena + hemodynamic instability + acute anemia strongly suggests acute upper GI hemorrhage.

Diagnosis: Acute upper GI bleeding, likely NSAID-induced peptic ulcer
2
Step 2 — Risk Stratify

Apply the Glasgow-Blatchford Score (GBS): BUN elevated, hemoglobin 8.2 g/dL (male), systolic BP 95 mmHg, tachycardia present, melena present. This yields a GBS ≥ 6, indicating high-risk status requiring inpatient management. A GBS of 0–1 would suggest low risk potentially suitable for outpatient management.

GBS ≥ 6 → High-risk; admit to ICU/monitored bed
3
Step 3 — Initial Resuscitation

Begin aggressive IV crystalloid resuscitation. Transfuse packed red blood cells targeting hemoglobin ≥ 7 g/dL (a restrictive transfusion strategy has been shown to improve outcomes in upper GI bleeding compared to a liberal strategy). Initiate an IV PPI infusion (e.g., pantoprazole 80 mg bolus followed by 8 mg/hr continuous infusion) to raise intragastric pH above 6, which stabilizes clots. Discontinue NSAIDs immediately. Place two large-bore peripheral IVs; type and crossmatch 4 units.

IV PPI bolus + drip, restrictive transfusion, stop NSAID
4
Step 4 — Endoscopic Intervention

Perform EGD within 24 hours of presentation (within 12 hours for high-risk patients). EGD reveals a 1.5 cm ulcer on the posterior duodenal wall with a visible vessel (Forrest classification IIa) at the base. This carries a ~43% rebleeding risk without intervention. Apply dual endoscopic therapy: epinephrine injection (1:10,000) plus thermal coagulation or hemoclip placement. Biopsies of the ulcer margins and antral mucosa are obtained for H. pylori testing.

Forrest IIa → Dual endoscopic hemostasis + H. pylori biopsy
5
Step 5 — Post-Procedure Management & Follow-Up

Continue IV PPI for 72 hours then transition to oral PPI (e.g., omeprazole 40 mg daily) for 8 weeks. H. pylori biopsy returns positive: initiate quadruple therapy (PPI + bismuth subsalicylate + metronidazole + tetracycline × 14 days) given rising clarithromycin resistance. Confirm eradication with urea breath test or stool antigen ≥ 4 weeks after completing antibiotics and ≥ 2 weeks off PPI. Counsel the patient to avoid NSAIDs; if analgesics are needed, recommend acetaminophen or, if an NSAID is absolutely required, the lowest-dose COX-2 selective agent with a co-prescribed PPI. Duodenal ulcers that are H. pylori-positive and successfully eradicated do not require repeat endoscopy. Gastric ulcers would require repeat EGD at 8–12 weeks to document healing and exclude malignancy.

Quadruple therapy → Confirm eradication → NSAID avoidance → No repeat EGD for DU

SECTION 7

Treatment Approaches — Strengths & Limitations

Therapy	Mechanism & Use	Limitations / Side Effects
Proton Pump Inhibitors	Irreversible H⁺/K⁺-ATPase inhibition; first-line for GERD, PUD, ZES, stress ulcer prophylaxis	Long-term: C. difficile risk, hypomagnesemia, osteoporotic fractures, B₁₂ deficiency, fundic gland polyps, possible CKD
H₂-Receptor Antagonists	Competitive H₂ blockade on parietal cells; second-line for GERD; nocturnal acid suppression	Tachyphylaxis with chronic use; less potent than PPIs; cimetidine → anti-androgenic effects, CYP450 inhibition
Sucralfate	Polymerizes in acidic pH to form protective barrier over ulcer base; stress ulcer prophylaxis in critically ill	Requires acidic environment (avoid with PPIs); impairs absorption of other drugs; constipation
Misoprostol	PGE₁ analog; replaces prostaglandins inhibited by NSAIDs; NSAID gastropathy prophylaxis	Diarrhea, abdominal cramping; absolutely contraindicated in pregnancy (abortifacient)
Triple / Quadruple Therapy	H. pylori eradication; PPI + clarithromycin + amoxicillin (triple) or PPI + bismuth + metronidazole + tetracycline (quadruple)	Rising clarithromycin resistance (>15% in many regions favors quadruple Rx); compliance challenges with 14-day regimens; metallic taste, nausea
Nissen Fundoplication	360° gastric wrap around LES; definitive anti-reflux surgery for refractory GERD	Gas-bloat syndrome, dysphagia, inability to belch/vomit; requires pre-op manometry to exclude motility disorder

Comparison of major upper GI pharmacologic and surgical therapies

💊

CLINICAL PEARL

When a board question describes a patient with recurrent peptic ulcers despite appropriate PPI therapy and negative H. pylori testing, consider Zollinger-Ellison syndrome (gastrinoma). The diagnosis is confirmed by a fasting serum gastrin level > 1000 pg/mL or a positive secretin stimulation test (paradoxical rise in gastrin > 120 pg/mL). ZES is associated with MEN1 (parathyroid adenoma + pituitary adenoma + pancreatic/duodenal gastrinoma), so check calcium and prolactin if ZES is confirmed.

SECTION 8

Connections to Advanced GI Oncology & Motility

Upper GI disorders serve as a gateway to more advanced pathology frequently tested on Step 2 and encountered in clinical clerkships. The progression from chronic inflammation to metaplasia to dysplasia to carcinoma — the Correa cascade — exemplifies how benign conditions such as H. pylori gastritis can culminate in gastric adenocarcinoma over decades. Similarly, the Barrett's metaplasia-dysplasia-adenocarcinoma sequence in the esophagus underscores the importance of surveillance programs. Understanding these cascades connects fundamental upper GI pathophysiology to oncologic principles including tumor staging (TNM), surgical candidacy, and systemic therapy.

Concept	Step 2 Foundation	Advanced Extension
Barrett's Esophagus	Intestinal metaplasia, surveillance intervals (no dysplasia: q3–5 yr; LGD: q6–12 mo; HGD: intervention)	Radiofrequency ablation, endoscopic mucosal resection, esophagectomy for intramucosal carcinoma; genomic biomarkers under investigation
Gastric Adenocarcinoma	Intestinal vs. diffuse (Lauren classification); Virchow node, Sister Mary Joseph nodule, Krukenberg tumor	HER2/neu overexpression → trastuzumab; PD-L1 expression → pembrolizumab; perioperative chemotherapy (FLOT regimen)
Achalasia	Bird's beak on barium swallow; manometry: absent peristalsis, incomplete LES relaxation; treatment with pneumatic dilation or Heller myotomy	Per-oral endoscopic myotomy (POEM); Chicago classification v4.0 manometric subtypes predicting treatment response
GIST	Submucosal mass, CD117 (c-KIT) positive on IHC; surgical resection	Imatinib (tyrosine kinase inhibitor) for unresectable/metastatic disease; mutational analysis (KIT exon 11 vs. PDGFRA D842V)

Step 2 foundations and their advanced clinical extensions

As you advance from Step 2 into clinical practice, the principles covered here — anatomic localization of pathology, systematic risk stratification, evidence-based H. pylori management, and judicious use of endoscopy — will form the scaffold upon which subspecialty gastroenterology and surgical oncology decision-making are built. Recognizing the clinical overlap between benign acid-related disease and early malignancy is perhaps the most critical skill, because timely identification of high-risk features can alter patient outcomes dramatically.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 40-year-old woman with rheumatoid arthritis has been taking naproxen 500 mg BID for 6 months. She now presents with epigastric pain. Explain the pathophysiologic mechanism by which NSAIDs predispose to peptic ulcer disease, and state which specific type of ulcer (gastric vs. duodenal) is more commonly caused by NSAIDs alone (without concurrent H. pylori infection).

Show answer

NSAIDs inhibit cyclooxygenase-1 (COX-1), the constitutive enzyme responsible for synthesizing prostaglandins PGE₂ and PGI₂ in the gastric mucosa. These prostaglandins normally maintain mucosal defense by stimulating mucus and bicarbonate secretion, promoting mucosal blood flow, and enhancing epithelial cell turnover. Without this prostaglandin-mediated protection, the mucosa becomes vulnerable to acid-pepsin attack even at normal acid levels. NSAIDs preferentially cause gastric ulcers (rather than duodenal ulcers) because the gastric mucosa has direct, prolonged topical exposure to the ingested drug and because NSAIDs do not increase acid secretion — they simply weaken the mucosal barrier.

Question 2: BASIC CALCULATION

A patient undergoes 24-hour ambulatory esophageal pH monitoring. Total recording time is 24 hours. The total time with esophageal pH < 4 is measured as 2 hours and 24 minutes. Calculate the percentage of total time with acid exposure and state whether this result is considered normal or abnormal based on the standard threshold of < 4.2% total acid exposure time.

Show answer

Convert 2 hours and 24 minutes to minutes: 2 × 60 + 24 = 144 minutes. Total recording time = 24 × 60 = 1440 minutes. Percentage acid exposure = (144 ÷ 1440) × 100 = 10.0%. The normal threshold for total acid exposure time is < 4.2%. This patient's 10.0% significantly exceeds the normal range, confirming pathologic acid reflux consistent with GERD. This objective measurement is particularly valuable when endoscopy is normal but symptoms persist, as it distinguishes true GERD from functional heartburn.

Question 3: INTERMEDIATE

A 62-year-old man presents with hematemesis. EGD reveals a duodenal ulcer with a clean base (Forrest class III). H. pylori stool antigen is positive. He takes low-dose aspirin for secondary prevention of coronary artery disease. Outline the appropriate management plan, including whether endoscopic hemostasis is required, the H. pylori eradication regimen, and how to address his aspirin use.

Show answer

A Forrest class III ulcer (clean base) carries a < 5% rebleeding risk and does not require endoscopic hemostasis; the patient can be started on oral PPI therapy. For H. pylori eradication, current ACG guidelines recommend either bismuth quadruple therapy (PPI + bismuth subsalicylate + metronidazole + tetracycline × 14 days) or concomitant therapy (PPI + clarithromycin + amoxicillin + metronidazole × 14 days), with quadruple therapy preferred in areas with clarithromycin resistance > 15%. Regarding aspirin, abruptly stopping it in a patient with established coronary artery disease carries a significant risk of thrombotic events. Evidence from the ATLAS trial and guidelines suggest resuming low-dose aspirin within 3–7 days once hemostasis is achieved, combined with a PPI for gastroprotection, as the cardiovascular mortality risk of aspirin cessation outweighs the modest increase in rebleeding risk.

Question 4: APPLIED

A 58-year-old obese male with a 15-year history of GERD undergoes surveillance EGD. Biopsies from the distal esophagus demonstrate intestinal metaplasia with goblet cells and low-grade dysplasia (LGD) confirmed by two expert GI pathologists. Describe the recommended surveillance and management strategy, including the role of endoscopic eradication therapy.

Show answer

Barrett's esophagus with confirmed low-grade dysplasia (LGD) is managed with endoscopic eradication therapy (EET), most commonly radiofrequency ablation (RFA), which has been shown in randomized trials (e.g., SURF trial) to significantly reduce the risk of progression to high-grade dysplasia and esophageal adenocarcinoma compared to surveillance alone. Before RFA, any visible mucosal irregularity should be resected by endoscopic mucosal resection (EMR) for staging purposes. The patient should be maintained on high-dose PPI therapy to control reflux and optimize the neosquamous epithelium that regenerates after ablation. Post-ablation surveillance includes EGD with biopsies at 3 months, then every 6 months for the first year, then annually. The diagnosis of LGD must be confirmed by a second expert GI pathologist because of significant interobserver variability — if only one pathologist confirms LGD, repeat EGD in 6 months with intensive surveillance may be appropriate. Weight loss counseling and lifestyle modifications are also essential.

Question 5: CRITICAL THINKING

A 45-year-old man presents with recurrent duodenal ulcers despite two courses of H. pylori eradication therapy (confirmed negative on repeat testing) and consistent PPI compliance. He also reports chronic secretory diarrhea. Labs reveal a fasting serum gastrin of 1,250 pg/mL. Construct a comprehensive differential for this presentation, explain how you would confirm the most likely diagnosis, localize the lesion, and outline the definitive management strategy, including screening for associated syndromes.

Show answer

The constellation of recurrent PUD refractory to standard therapy, markedly elevated fasting gastrin (> 1000 pg/mL), secretory diarrhea (from massive acid output overwhelming intestinal absorption), and confirmed H. pylori eradication is classic for Zollinger-Ellison syndrome (ZES) caused by a gastrinoma. The differential for hypergastrinemia also includes PPI use (must hold PPIs ≥ 1 week before testing), chronic atrophic gastritis, renal failure, and retained gastric antrum post-surgery — but none of these produce the clinical triad seen here. To confirm ZES, perform a secretin stimulation test: IV secretin (2 mcg/kg) causes a paradoxical rise in serum gastrin > 120 pg/mL above baseline in gastrinoma patients (normal tissue would decrease gastrin). Tumor localization uses somatostatin receptor scintigraphy (OctreoScan) as first-line, supplemented by endoscopic ultrasound (especially for duodenal wall tumors < 1 cm) and CT/MRI for hepatic metastases. Approximately 25% of gastrinomas occur in the setting of MEN1 (autosomal dominant), so screen for primary hyperparathyroidism (calcium, PTH) and pituitary adenomas (prolactin, IGF-1, MRI sella). Definitive management of sporadic gastrinoma is surgical resection (enucleation or pancreaticoduodenectomy depending on size and location). In MEN1-associated gastrinomas, which are often multifocal and carry lower surgical cure rates, long-term high-dose PPI therapy controls acid hypersecretion, with surgery reserved for tumors > 2 cm to prevent hepatic metastases.

SUMMARY

Upper Gastrointestinal Disorders — Summary

Summary

Upper GI disorders represent a clinically interconnected spectrum driven by the imbalance between aggressive factors (acid, pepsin, H. pylori, NSAIDs) and mucosal defense mechanisms (prostaglandins, mucus-bicarbonate barrier, blood flow). GERD arises from LES dysfunction and is managed with lifestyle modifications, PPIs, and anti-reflux surgery in refractory cases. Peptic ulcer disease requires identification and treatment of the underlying cause — H. pylori eradication and NSAID cessation — alongside acid suppression. Upper GI bleeding demands rapid risk stratification (Glasgow-Blatchford Score), hemodynamic resuscitation, IV PPI therapy, and timely endoscopy with dual hemostatic therapy for high-risk lesions.

Barrett's esophagus surveillance and endoscopic eradication therapy (RFA) are critical for reducing the risk of progression to esophageal adenocarcinoma. Refractory ulcers in the absence of H. pylori or NSAIDs should raise suspicion for Zollinger-Ellison syndrome (confirmed by secretin stimulation test), with screening for MEN1. Mastery of the anatomic, pathophysiologic, and therapeutic framework reviewed here provides the clinical reasoning tools needed for both USMLE Step 2 vignettes and real-world patient care.